International Journal of Medical and Pharmaceutical Research
2023, Volume-4, Issue-3 doi: 10.5281/zenodo.7945338
Original Article
Comparison of 0.75% Epidural Ropivacaine with and without Fentanyl for Prolongation of Postoperative Analgesia in Adults for Elective Lower Limb Orthopaedics Surgery- An Observational Study
 ,
 ,
Published
May 17, 2023
Abstract
Introduction: Epidural analgesia is an effective postoperative analgesia for surgical procedures. The use of Ropivacaine with adjuvant like Fentanyl is a newer development in the neuraxial blockade and the studies are scarce, so this study to compare the onset and duration of motor and sensoryblockade, efficacy of post-operative analgesia and side-effects seen with 0.75% Ropivacaine with Fentanyl and 0.75% Ropivacaine without any adjuvant in adult lower limb orthopaedics surgery. Method: 84 patients were divided into two groups of 42 each. Group RF received 15ml of 0.75% Ropivacaine plus 50micrograms of Fentanyl (total=16ml) and Group R received 15ml 0.75% Ropivacaine plus 1 cc NS (total = 16ml) epidurally. Duration of sensory and motor block was observed intraoperatively and postoperatively along with pain scores (Visual Analogue Scale VAS) and side effects (nausea, vomiting, bradycardia, hypotension). Results: The groups were demographically comparable. Duration of sensory block was longer in RF group and so was haemodynamic stability and delayed requirement of rescue analgesia. None of the groups showed any side effects. Conclusion: We conclude that 0.75% Ropivacaine with Fentanyl provides an excellent post-operative analgesia, with no side effects and stable haemodynamics with good patient satisfaction than 0.75% ropivacaine without adjuvant and can be used effectively in all lower limb surgeries
Recommended Articles
Loading Image...
Volume-4, Issue-3
Citations
816 Views
265 Downloads
Share this article
License
Copyright (c) International Journal of Medical and Pharmaceutical Research
pdf Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.
All papers should be submitted electronically. All submitted manuscripts must be original work that is not under submission at another journal or under consideration for publication in another form, such as a monograph or chapter of a book. Authors of submitted papers are obligated not to submit their paper for publication elsewhere until an editorial decision is rendered on their submission. Further, authors of accepted papers are prohibited from publishing the results in other publications that appear before the paper is published in the Journal unless they receive approval for doing so from the Editor-In-Chief.
IJMPR open access articles are licensed under a Creative Commons Attribution-ShareAlike 4.0 International License. This license lets the audience to give appropriate credit, provide a link to the license, and indicate if changes were made and if they remix, transform, or build upon the material, they must distribute contributions under the same license as the original.
Logo
International Journal of Medical and Pharmaceutical Research
About Us
The International Journal of Medical and Pharmaceutical Research (IJMPR) is an EMBASE (Elsevier)–indexed, open-access journal for high-quality medical, pharmaceutical, and clinical research.
Follow Us
© Copyright IJMPR | All Rights Reserved